AML
Oryzon Genomics announces publication of phase 2a ALICE trial results
June 4, 2024Medical Communications AML, Oncology, Oryzon genomics, acute myeloid leukaemia, clinical trial
Oryzon Genomics has announced that the final results from its phase 2a ALICE study have been published online in The …
Researchers find Achilles’ heel protein in leukaemia
April 26, 2019Medical Communications AML, Edinburgh, Protein, YTHDF2, blood cancer, drug targets, leukaemia
An international team of researchers have identified an “Achilles’ heel” protein that could lead to the development of novel treatments …
Pfizer’s Daurismo becomes first of its kind to secure FDA approval in acute myeloid leukaemia
November 22, 2018Research and Development, Sales and Marketing AML, Daurismo, FDA, Pfizer, US, leukaemia
Pfizer has revealed that the FDA has chosen to approve its Daurismo (glasdegib) for the treatment of newly-diagnosed acute myeloid …
MSD teams up with Harvard to develop new leukaemia treatments
March 24, 2016Medical Communications, Research and Development AML, Harvard, MSD, leukaemia
MSD has entered a new collaboration with Harvard University aimed at developing innovative new small-molecule therapeutics for leukaemia and other …
Mixed results for new leukaemia drugs
December 9, 2014Research and Development, Sales and Marketing AML, Bayer, Nexavar, Qinprenzo, Sunesis Pharmaceuticals, sorafenib
Two trials of new drugs for acute myeloid leukaemia (AML) have shown promising results in younger and older groups of …
Daiichi Sankyo pays $410m for Ambit Biosciences
September 29, 2014Sales and Marketing AML, Daiichi Sankyo, ambit biosciences, quizartinib
Daiichi Sankyo has bought San Diego-based Ambit Biosciences in a deal aimed at shoring up the Japanese company’s cancer research. …
Boehringer targets AML
March 1, 2013Research and Development, Sales and Marketing AML, Boehringer
Boehringer Ingelheim is to begin a pivotal trial of its investigative treatment volasertib in patients with acute myeloid leukaemia (AML). …
Trial failures threaten UK biotech
February 18, 2011Research and Development AML, AS1411, AS1413, Antisoma, Juvista, Renovo, UK biotech, acute myeloid leukaemia, anti-scarring, biotech
A number of late stage failures from British biotech firms have left a looming question mark over the future of …
Pfizer withdraws blood cancer drug in US
June 22, 2010Sales and Marketing AML, Mylotarg, Pfizer, blood cancer
The US regulatory body has withdrawn Pfizer’s leukaemia drug Mylotarg after it was linked to a number of deaths, and …
Antisoma stages comeback with promising cancer drugs
May 20, 2010Research and Development AML, Antisoma, chemotherapy, leukaemia
UK biotech Antisoma is looking to put previous late-stage trial failures behind it by focusing on two new cancer drugs. …
